|
Title
|
Content
|
 |
1. Bacterial Meningitis
2. Viral Meningitis
3. Encephalitis
4. Brain Abscess
|
 |
1. Introduction (slide 1~10)
2. Symptoms and signs (slide 11~18)
3. Management of bacterial meningitis (slide 19~34)
4. Other CNS infections (slide 35~50)
|
 |
1. The 4 pathologic stages
2. The best best diagnostic imaging clues
3. The epidemiology and the empirical choice of antibiotics
|
 |
1. 流行性腦脊髓膜炎病例定義
2. 從疾病概述、流行病學、預防措施談到防治工作
3. 應在疑似時即予通報,切勿等待細菌檢驗結果,並及時使用抗生素。
|
 |
1. Meningoencephalitis syndrome with associated CSF abnormalities persists at least 4 weeks
2. Infectious and noninfectious causes
3. The 5 key historical clues and the laboratory evaluation
|
 |
1.Bacteriology and laboratory (slide 2~25)
2.Imaging (slide 26~33)
3.Prognosis (slide 35~38)
4. Treatment (slide 39~49)
|
 |
1. Infectious and noninfectious etiologies
2. The main cause: Angiostrongyliasis
3. The most important DDx: Gnathostomiasis
|
 |
1. Clinical features and pictures of cryptococcosis
2. Manisfestations of CNS cryptococcosis
3. How to administer amphotericin-B?
|
 |
1. CO: How much is too much?
2. MR imaging of CO intoxication
3. Puse oximeter overesteimates SO2
|
 |
1. Type I = Reflex sympathetic dystrophy syndrome; type II= causalgia
2. Thres stages and the Three clinical certeria
3. Managment of complex regional pain syndrome
|
| |
|
 |
1. 多發性硬化症的流行病學及症狀
2. 分類:復發緩解型 、次發進展型 、原發進展型
3. 多發性硬化症的診斷及治療
|
 |
1. PD病人的症狀治療
2. 左多巴藥 / COMT抑制劑 / 多巴胺促動劑 / MAO-B抑制劑 / 抗乙醯膽鹼製劑 / Amantadine
3. 如何治療運動波動 / 異動症
|
 |
1. 有關癲癇的普通常識
2. 一般發作及癲癇重積狀態之處置
3. 分辨真假癲癇
|
 |
1. Causes of epilepsy-related deaths
2. Criteria for SUDEP
3. Risk factors for SUDEP
|
 |
1. Epidemiology and risk factors
2. Probable mechanism
3. Summary (slide 41~45)
4. Case scenerio (slide 48~52)
|
 |
1. Tetrad of transverse myelitis = triad of myelopathy + pain
2. Differential diagnosis
3. Management of acute and chronic myelopathy
|
 |
1. Introduction (slide 1~10) & Epidemiology (slide 11~19)
2. Etiology and pathophysiology (slide 20~32)
3. Clinical features (slide 33~40)
4. Diagnosis (slide 41~72)
|